HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

LY3214996

protein kinase inhibitor

Also Known As:

6,6-Dimethyl-2-(2-((2-methylpyrazol-3-yl)amino)pyrimidin-4-yl)-5-(2-morpholin-4-ylethyl)thieno(2,3-c)pyrrol-4-one

Networked: 11 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrroles: 369
      - LY3214996: 11
    - Pyrazoles: 61
      - LY3214996: 11

Experts

1.	Bhagwat, Shripad V: 2 articles (01/2021 - 01/2020)
2.	Tiu, Ramon V: 2 articles (01/2021 - 01/2020)
3.	Buzdin, Anton A: 1 article (01/2022)
4.	Ivanenko, Karina A: 1 article (01/2022)
5.	Khabusheva, Elmira R: 1 article (01/2022)
6.	Kudryavtseva, Anna V: 1 article (01/2022)
7.	Lebedev, Timofey D: 1 article (01/2022)
8.	Mareeva, Sofia R: 1 article (01/2022)
9.	Morozov, Alexey V: 1 article (01/2022)
10.	Prassolov, Vladimir S: 1 article (01/2022)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2020 - "LY3214996 showed dose-dependent tumor growth inhibition and regression in xenograft models harboring ERK pathway alterations. " 01/01/2020 - "ERK Inhibitor LY3214996 Targets ERK Pathway-Driven Cancers: A Therapeutic Approach Toward Precision Medicine." 01/01/2023 - "Informed by these results, we evaluated the efficacy of the CDK4/6 inhibitor, abemaciclib, and the ERK1/2 inhibitor, LY3214996, alone and in combination in reducing PNF tumor burden in Nf1flox/flox;PostnCre mice. " 01/01/2021 - "LY3214996 combined with sorafenib enhanced the anti-tumor effects of sorafenib in HCC. " 01/01/2021 - "In this work, we investigated whether adding LY3214996, a selective ERK1/2 inhibitor, to sorafenib would increase the anti-tumor effectiveness of sorafenib to HCC cells. "
2.	Lung Neoplasms (Lung Cancer) 01/01/2021 - "Here, we show that intermittent application of the novel and selective ATP-competitive ERK1/2 inhibitor LY3214996 exerts single-agent activity in patient-derived xenograft (PDX) models of RAS-mutant lung cancer. " 01/01/2022 - "Using ERK1/2 and downstream kinase ELK1 reporter cell lines of lung cancer (H1299; NRASQ61K), colon cancer (HCT-116; KRASG13D), neuroblastoma (SH-SY5Y), and leukemia (U937), we examined the relationship between ERK inhibition and drug-induced toxicity for five ERK inhibitors: SCH772984, ravoxertinib, LY3214996, ulixertinib, and VX-11e, as well as one MEK inhibitor, PD0325901. "
3.	Colorectal Neoplasms (Colorectal Cancer) 01/01/2020 - "LY3214996 also exhibited synergistic combination benefit with a pan-RAF inhibitor in a KRAS-mutant colorectal cancer xenograft model. "
4.	Stomach Neoplasms (Stomach Cancer) 01/01/2021 - "Ly3214996, an inhibitor of ERK signal pathway, was administered to assess the effects of BANCR overexpression on gastric cancer cell with cisplatin-treated resistance. " 01/01/2021 - "Ly3214996 treatment abolished the BANCR overexpression-mediated gastric cancer cell cisplatin resistance via regulating the phosphorylation of ERK protein. "
5.	Osteosarcoma (Osteogenic Sarcoma) 01/01/2021 - "LY3214996, a highly selective inhibitor of the ERK1/2 pathway, was able to antagonize the effects of PHA-665752 in osteosarcoma. "

Related Drugs and Biologics

1.	abemaciclib
2.	Cyclin-Dependent Kinase 4
3.	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)
4.	Mitogen-Activated Protein Kinase Kinases (MEKs)
5.	Sirolimus (Rapamycin)
6.	Interleukin-8 (Interleukin 8)
7.	Interleukin-6 (Interleukin 6)
8.	Biomarkers (Surrogate Marker)
9.	Proteins (Proteins, Gene)
10.	Phosphotransferases (Kinase)

Related Therapies and Procedures

1.	Precision Medicine